Analysed EISAI CO LTD (ESALF:OTCMKTS) News Sources
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
09-04-2026
yahoo.com
Eisai (TSE:4523) Valuation Check As Recent Momentum Meets Mixed Long Term Returns
05-04-2026
yahoo.com
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock
27-03-2026
yahoo.com
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
26-03-2026
yahoo.com
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
23-03-2026
yahoo.com
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
20-03-2026
yahoo.com
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies
18-03-2026
yahoo.com
Evaluating Eisai (TSE:4523) After Mixed Returns And A Modest Undervaluation Signal
13-03-2026
yahoo.com
What is the current price of EISAI CO LTD (ESALF:OTCMKTS)?
The current price of EISAI CO LTD (ESALF:OTCMKTS) is $30.
EISAI CO LTD (ESALF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of EISAI CO LTD (ESALF:OTCMKTS) since the previous trading day is $0.
EISAI CO LTD (ESALF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of EISAI CO LTD (ESALF:OTCMKTS) since the previous trading day is 0%.
What is the most recent average sentiment score for EISAI CO LTD (ESALF:OTCMKTS)?
The most recent average sentiment score for EISAI CO LTD (ESALF:OTCMKTS) is 77 out of 100.
What is the most recent average sentiment for EISAI CO LTD (ESALF:OTCMKTS)?
The most recent sentiment for EISAI CO LTD (ESALF:OTCMKTS) is .
SEC-8K** Filing Available For EISAI CO LTD (ESALF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.